A bench-to-bedside review highlights zongertinib's potential to improve treatment outcomes in HER2-mutant NSCLC, suggesting significant advancements in therapy.
Zongertinib is the first oral TKI approved for HER2-mutant NSCLC and will provide patients with a convenient, tolerable and effective treatment option in an area of significant unmet need. Next steps include its potential transition to a first-line setting, identification of additional indications, and development of novel combination regimens.
No takes yet. Share an insight, caveat, or question.
Choe et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: